Worth reading
39Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.This transaction
Name of transactionCounterparty (target company)創イノベーション株式会社
Disclosing companyImageONE Co.,Ltd.
TimelineThe spacing between the points is proportional to the actual number of days.
Consideration and expenses
Type of ConsiderationShares (share exchange; allocation details: Not disclosed)
Procedures and assumptions
Conditions Precedent to ExecutionThe prospects for commercializing the technology to separate tritium become clear
Management structure after acquisitionBusiness integration under which the Company will be the wholly owning parent company and 創イノベーション株式会社 will be the wholly owned subsidiary
| Item | Details |
|---|---|
| Transaction name | Name of transaction |
| Counterparty name | 創イノベーション株式会社 |
| Name of the Subject Company | 創イノベーション株式会社 |
| Type of Consideration | Shares (share exchange; allocation details: Not disclosed) |
| Date of board resolution | 26 March 2026 (the change in schedule was resolved at the Board of Directors meeting held today). The Board of Directors meeting to approve the share exchange agreement is scheduled for March 2027 |
| Contract Date | March 2027 (scheduled) |
| Execution Date / Effective Date | June 2027 (scheduled) |
| Conditions Precedent to Execution | The prospects for commercializing the technology to separate tritium become clear |
| Management structure after acquisition | Business integration under which the Company will be the wholly owning parent company and 創イノベーション株式会社 will be the wholly owned subsidiary |
Items this document does not state (23)
Business Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Impact on Business PerformanceValuation methodologyIndependent valuation institutionSpecial Committee
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This is because the prospects for commercializing the technology to separate tritium remain unclear at this time. The Company will continue its validation research with 創イノベーション and the Omura Laboratory of the Faculty of Science and Technology at Keio University, while proceeding with the refinement of the technology and considering its commercialization and technological applications.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.